Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $20.1429.

LXEO has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Chardan Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a report on Monday, May 11th.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $4.93 on Friday. The company has a market capitalization of $387.10 million, a P/E ratio of -3.40 and a beta of 1.38. The firm’s fifty day simple moving average is $5.40 and its 200-day simple moving average is $6.90. Lexeo Therapeutics has a 1-year low of $3.60 and a 1-year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. On average, equities research analysts predict that Lexeo Therapeutics will post -1.23 earnings per share for the current year.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the sale, the chief executive officer directly owned 340,106 shares in the company, valued at $1,935,203.14. This trade represents a 13.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 59,644 shares of company stock valued at $336,462. Company insiders own 2.00% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

Several institutional investors have recently made changes to their positions in the business. Allworth Financial LP boosted its position in Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after buying an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after buying an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $37,000. California State Teachers Retirement System boosted its position in Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC acquired a new position in Lexeo Therapeutics in the second quarter valued at about $50,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.